Fox Run Management L.L.C. Purchases New Shares in Dynavax Technologies Co. (NASDAQ:DVAX)

Fox Run Management L.L.C. purchased a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 69,185 shares of the biopharmaceutical company’s stock, valued at approximately $883,000. Fox Run Management L.L.C. owned approximately 0.05% of Dynavax Technologies as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in DVAX. PDT Partners LLC bought a new stake in Dynavax Technologies in the third quarter valued at $3,967,000. Nordea Investment Management AB boosted its holdings in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after buying an additional 232,690 shares in the last quarter. Barclays PLC boosted its holdings in shares of Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after buying an additional 82,449 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter valued at $990,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

DVAX opened at $13.82 on Friday. The stock has a 50-day moving average price of $13.22 and a 200-day moving average price of $12.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.71 billion, a PE ratio of 76.78 and a beta of 1.23. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. Finally, The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.